Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBlue Cross MA Toxicology Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MassachusettsPolicy 812

    Specialty Laboratory Testing - Toxicology and Pharmacogenetics

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 812 alerts

    Get alerted when Policy 812 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical-necessity requirements for specialty laboratory testing related to metal and lead toxicity, including inpatient prior-authorization requirements and applicable coding information.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicySpecialty Laboratory Testing - Toxicology and Pharmacogenetics
    Policy CodePolicy 812
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain preauthorization for covered services performed in the inpatient setting.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Metals specifically addressed
    9Listed metal-toxicity codes
    ≤6 yearsChild lead-testing pathway
    RequiredInpatient preauthorization
    Blood onlyLead specimen for diagnosis

    Medical Necessity and Coverage Criteria

    Metal Toxicity Tests

    Metal toxicity testing for aluminum, mercury, arsenic, cadmium, and manganese is medically necessary when ANY of the following pathways is met:

    ANY of the following

    • The member is being monitored for previously abnormal levels of the metal(s) being evaluated.
    • The member has a known exposure to the metal(s) being evaluated.
    • The member has renal disease that is not explained by other factors.
    • The member has bilateral peripheral neuropathy that is not explained by other factors.
    • The member has acute changes in mental function that are not attributable to another established diagnosis.
    • The member has acute inflammation of the laryngeal or nasal epithelium that is not explained by other factors.
    • Both of the following

      • The member has nonspecific signs or symptoms, such as anemia, impaired speech and/or hearing function, lethargy, fatigue, abdominal discomfort, constipation, or vomiting.
      • The member has a plausible exposure to the metal(s) being evaluated, such as through a hobby or professional activity, dialysis, or contaminated water or soil.

    Lead Toxicity Tests

    Blood lead toxicity testing is medically necessary when ANY of the following pathways is met:

    ANY of the following

    • The member has a known exposure to lead.
    • The member is an immigrant, refugee, or adoptee from outside the United States.
    • The member is being monitored for previously elevated blood lead levels.
    • Both of the following

      • The member is 6 years of age or younger.
      • ONE of the following

    Specific Metal Testing

    Specific metal toxicity testing is medically necessary when the clinical evaluation supports concern for poisoning by the specific metal being tested.

    ONE of the following supports specific metal testing

    • A relevant history of exposure to the specific metal is present.
    • The member has unexplained renal disease.
    • The member has bilateral peripheral neuropathy.
    • The member has acute changes in mental function.
    • The member has acute inflammation of the laryngeal or nasal epithelium.

    Childhood Lead Testing

    Blood lead level testing is medically necessary for children at increased risk for lead exposure. Increased-risk children include those meeting ANY of the following criteria:

    ANY of the following

    • The child lives in or spends time in a house or building built before 1978.
    • The child is from a low-income household.
    • The child is an immigrant, refugee, or recently adopted child from a less developed country.
    • The child lives with or spends time with someone who works with lead or has hobbies that expose the child to lead.
    • The child is enrolled in Medicaid and is due for required testing at 12 or 24 months, or at 24–72 months when no prior testing is on record.

    Metal toxicity testing is considered investigational for all other indications not meeting the medical-necessity criteria above.

    Urine lead toxicity testing is considered investigational for all indications.

    Blood lead toxicity testing is considered investigational for all other indications not meeting the medical-necessity criteria above.

    Routine heavy-metal screening should not be performed for nonspecific symptoms in the absence of excessive or plausible metal exposure. Testing should be directed toward a specific metal when the exposure history and clinical findings support concern for poisoning by that metal.

    Routine monitoring of aluminum levels in individuals receiving hemodialysis is not recommended. Preventive management should instead address long-term use of aluminum-containing phosphate binders and aluminum contamination of dialysate.

    Universal lead screening during pregnancy is not recommended. Testing should be focused on pregnant or lactating individuals with known lead exposure or increased risk factors for lead exposure.

    Hair and urine lead levels should not be performed because they provide no useful diagnostic information. Blood lead measurements are the only reliable way to diagnose lead poisoning.

    Coding and Testing Pathways

    Metal Toxicity Tests — CPT CodesCPTCovered
    82108Aluminum
    82175Arsenic
    82300Cadmium
    83018Heavy metal (eg, antimony, arsenic, barium, beryllium, bismuth, gadolinium, mercury); quantitative, each, not elsewhere specified
    83655Lead
    83785Manganese
    83825Mercury, quantitative
    83885Nickel
    84202Protoporphyrin, RBC; quantitative
    Lead Toxicity Tests — CPT CodesCPTCovered
    83655Lead
    Child lead-testing pathway
    Age threshold6 years of age or younger
    Qualifying exposure pathwayIncreased risk for lead exposure, such as living in or frequenting a home built before 1978
    Additional qualifying pathwaysSigns or symptoms of lead toxicity, or being a newborn at risk because of elevated maternal blood lead levels during gestation
    Older-child lead-testing pathway
    Age threshold7 years of age or older
    Exposure requirementIncreased risk for lead exposure, such as inhalation of lead-containing dust through a hobby or professional activity or consumption through contaminated water

    Provider Requirements and Denial Risks

    Prior Authorization

    Inpatient Prior Authorization Required

    Obtain precertification or preauthorization before performing any service described in this policy on an inpatient basis. This requirement applies to all products.

    Documentation Required

    Document Exposure History and Clinical Findings

    Document the specific metal or lead concern, relevant exposure history, clinical findings, and any prior abnormal levels. Testing should be tied to a plausible concern for poisoning by the metal being evaluated.

    • Identify the metal of concern and whether the member is being monitored for previously abnormal levels or has a known exposure.
    • Record compatible findings, including unexplained renal disease, bilateral peripheral neuropathy, acute mental-function changes, acute laryngeal or nasal inflammation, or lead-toxicity findings such as impaired learning, speech or hearing, lethargy, fatigue, abdominal discomfort, constipation, vomiting, or weight loss.

    Policy Background

    Specialty laboratory testing may be used to evaluate individuals with heavy-metal exposure, symptoms of toxicity, or an elevated risk of exposure. Testing should target a specific suspected metal and be supported by a relevant exposure history and compatible clinical findings. Indiscriminate testing for nonspecific symptoms may identify detectable or abnormal results that do not indicate poisoning and can lead to unnecessary concern.

    Key Definitions

    Specific metal testing
    Specific concernConcern for poisoning by a particular metal
    Exposure supportA credible and appropriate exposure history involving the suspected metal
    Clinical supportPhysical or clinical findings consistent with poisoning by that metal
    Blood lead measurement
    Required measurementBlood lead measurement
    Diagnostic roleThe only reliable method identified for diagnosing lead poisoning
    Methods not recommended
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicySpecialty Laboratory Testing - Toxicology and Pharmacogenetics
    Policy CodePolicy 812
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain preauthorization for covered services performed in the inpatient setting.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Testing PathwaysProvider Requirements and Denial RisksPolicy BackgroundKey Definitions
    The member is at increased risk for lead exposure, such as living in or frequenting a home built before 1978.
  1. The member has signs or symptoms of lead toxicity, such as impaired speech and/or hearing function, decreased memory and learning, lethargy, fatigue, abdominal discomfort, constipation, vomiting, or weight loss.
  2. The member is a newborn at risk for lead poisoning due to elevated maternal blood lead levels during gestation.
  3. All of the following

    • The member is 7 years of age or older.
    • The member is at increased risk for lead exposure, such as through inhalation of lead-containing dust due to a hobby or professional activity or consumption via a contaminated water source.
    • The member has signs or symptoms of lead toxicity, such as impaired speech and/or hearing function, decreased memory and learning, lethargy, fatigue, abdominal discomfort, constipation, vomiting, or weight loss.
  4. Both of the following

    • The member is pregnant or lactating.
    • The member is at increased risk for lead exposure, such as recent immigration to the United States, pica behavior, culturally specific indications, a low-income family, or potential inhalation of lead-containing dust through a hobby or professional activity.
  5. Clinical requirementSigns or symptoms of lead toxicity, including impaired speech or hearing, decreased memory and learning, lethargy, fatigue, abdominal discomfort, constipation, vomiting, or weight loss
  6. For nonspecific symptoms, document the relevant exposure concern and why the findings are compatible with the suspected metal toxicity.
  7. Documentation Required

    Record the Complete Exposure Risk Profile

    Capture the exposure circumstances that support testing, especially when symptoms are nonspecific. A focused history should address occupational, household, environmental, behavioral, travel, and medical risks.

    • Occupational or hobby exposure, including work or activities involving metals, dust, renovation, mining, smelting, battery recycling, or lead.
    • Household and environmental exposure, including older housing, contaminated water or soil, lead exposure from another household member, and proximity to contaminated sites.
    • Behavioral, cultural, and product-related risks, including pica, herbal or Ayurvedic remedies, lead-glazed ceramics, imported cosmetics or foods, and other culturally specific exposures.
    • Travel or immigration history, including recent immigration and immigrant, refugee, or adoptee status where relevant.
    • Medical and reproductive history, including dialysis, pregnancy or lactation, maternal blood lead elevation during gestation, prior elevated blood lead levels, and follow-up of an initially high result.

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Denial Risk

    Avoid Unsupported Screening and Specimens

    Do not order nonspecific heavy-metal screening solely for vague symptoms without a relevant exposure history or compatible clinical findings. Hair and urine lead specimens are unsupported for diagnosis and should not be performed.

    • Order testing for a specific metal only when the history and physical examination support concern for poisoning by that metal.
    • Avoid indiscriminate screening of asymptomatic individuals or members with nonspecific symptoms when no excessive exposure is identified.
    • Use a blood specimen for lead diagnosis; hair and urine lead levels provide no useful diagnostic information.
    Hair and urine lead levels provide no useful diagnostic information and should not be performed